S&P Futures
4,087.50 +7.50 (+0.18%) Dow Futures
33,118.00 +74.00 (+0.22%) Nasdaq Futures
13,080.00 -2.00 (-0.02%) Russell 2000 Futures
1,786.60 +6.50 (+0.37%) Crude Oil
74.90 +0.53 (+0.71%) Gold
1,998.50 +0.80 (+0.04%)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 9.10 |
| Open | 9.22 |
| Bid | 8.50 x 800 |
| Ask | 11.10 x 900 |
| Day's Range | 8.82 - 9.24 |
| 52 Week Range | 8.10 - 40.10 |
| Volume | |
| Avg. Volume | 1,442,150 |
| Market Cap | 473.805M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.40 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.17 |
- Business Wire
CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association
BRISBANE, Calif., March 23, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International Pediatric Transplant Association (IPTA) taking place March 25-28, 2023, in Austin, Texas.
- Insider Monkey
CareDx, Inc (NASDAQ:CDNA) Q4 2022 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Fourth Quarter 2022 Earnings Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Greg Chodaczek. Please go ahead. Greg Chodaczek: Good afternoon […]
- Business Wire
The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance
BRISBANE, Calif., March 07, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the issuance of a new position statement by the American Society of Transplant Surgeons (ASTS) supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart.
